Abstracts

Modified Atkins Diet in Children with Epilepsy with Eyelid Myoclonia (Jeavons Syndrome)

Abstract number : 3.325
Submission category : 10. Dietary Therapies (Ketogenic, Atkins, etc.)
Year : 2023
Submission ID : 70
Source : www.aesnet.org
Presentation date : 12/4/2023 12:00:00 AM
Published date :

Authors :
Presenting Author: Watuhatai Paibool, MD – The University of Chicago Medicine

Douglas Nordli, MD – The University of Chicago Medicine; Chalongchai Phitsanuwong, MD – The University of Chicago Medicine; Stephanie Schimpf, RD – The University of Chicago Medicine

Rationale: Epilepsy with eyelid myoclonia (EEM) or Jeavons syndrome is considered a genetic generalized epilepsy with a typical age of onset in childhood. Many types of seizures can be observed, including eyelid myoclonia, absence, generalized tonic-clonic, and myoclonic seizures. Seizures tend to be difficult to control requiring polypharmacy treatment or become drug-resistant. Dietary therapy, particularly with Modified Atkins Diet (MAD), as a treatment of seizures in this syndrome has rarely been studied. We report efficacy and tolerability of MAD in children with epilepsy with eyelid myoclonia.

Methods: We reviewed medical records of children with EEM treated at the University of Chicago Ketogenic Diet program from 2017 to 2022. Patients demography, seizure characteristics, electroencephalogram findings, response to treatment and adverse effects were reviewed.

Results: Six patients with EEM were identified. Average age of seizure onset was six (2-11) years and an average age when the MAD started was 10.7 (6-15) years. All patients were started on MAD and completed at least 6 months on the diet at the time of report. An average of four (0-9) anti-seizure medications (ASM) had been tried prior to the MAD. All patients achieved ketosis with an average level of serum beta-hydroxybutyrate of 1.9 (1.03-3.61) mmol/L. At the six month follow-up visit, all patients (100%) experienced a greater than 50% seizure reduction, 3/6 patients (50%) had more than 90% seizure reduction, 1/6 patients (17%) became seizure-free. All seizure types demonstrated a greater than 80% reduction in frequency.  Absence and myoclonic seizures showed the greatest reduction with 100% seizure reduction. Eyelid myoclonia and generalised tonic-clonic seizures showed more than 80% seizure reduction. Moreover, all patients reported improvement in alertness, mood, and concentration. Initial weight loss and mild gastrointestinal disturbances were reported in 2/6 patients (33%) and corrected with dietary adjustment.

Conclusions:

The Modified Atkins Diet has shown to be effective and well-tolerated for children with EEM in our study. Cognitive improvement has also been subjectively reported in all patients. Adverse effects are tolerable and correctable. The MAD, therefore, may be considered as a treatment option for patients with epilepsy with eyelid myoclonia.



Funding: None

Dietary Therapies (Ketogenic, Atkins, etc.)